(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Rani Therapeutics Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RANI's revenue for 2026 to be $1,514,750,218, with the lowest RANI revenue forecast at $1,514,750,218, and the highest RANI revenue forecast at $1,514,750,218. On average, 1 Wall Street analysts forecast RANI's revenue for 2027 to be $4,016,094,370, with the lowest RANI revenue forecast at $4,016,094,370, and the highest RANI revenue forecast at $4,016,094,370.
In 2028, RANI is forecast to generate $5,070,902,221 in revenue, with the lowest revenue forecast at $2,259,084,432 and the highest revenue forecast at $7,882,720,011.